Literature DB >> 15566349

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.

Vincenzo Pitini1, Diana Teti, Carmela Arrigo, Maria Righi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15566349     DOI： 10.1111/j.1365-2141.2004.05206.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  16 in total

Review 1.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 2.  Therapeutic approaches to patients with hypereosinophilic syndromes.

Authors:  Hans-Uwe Simon; Amy Klion
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

Review 3.  Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

Authors:  Fei Li Kuang; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Nov - Dec

4.  CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Christophe Roumier; Hélène Aubert; Martine Avenel-Audran; Nathalie Grardel; Stéphanie Poulain; Delphine Staumont-Sallé; Julien Seneschal; Gilles Salles; Kamel Ghomari; Louis Terriou; Christian Leclech; Chafika Morati-Hafsaoui; Franck Morschhauser; Olivier Lambotte; Félix Ackerman; Jacques Trauet; Sandrine Geffroy; Florent Dumezy; Monique Capron; Catherine Roche-Lestienne; Alain Taieb; Pierre-Yves Hatron; Sylvain Dubucquoi; Eric Hachulla; Lionel Prin; Myriam Labalette; David Launay; Claude Preudhomme; Jean-Emmanuel Kahn
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 5.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 6.  Primary eosinophilic disorders: a concise review.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 7.  Novel targeted therapies for eosinophilic disorders.

Authors:  Michael E Wechsler; Patricia C Fulkerson; Bruce S Bochner; Gail M Gauvreau; Gerald J Gleich; Tim Henkel; Roland Kolbeck; Sameer K Mathur; Hector Ortega; Jatin Patel; Calman Prussin; Paolo Renzi; Marc E Rothenberg; Florence Roufosse; Dagmar Simon; Hans-Uwe Simon; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

Review 8.  Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

Authors:  Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 9.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

Review 10.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2009-08-19       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.